We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics


DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App

Diasorin CE Marks New Simplexa Flu A/B & RSV Direct Gen II Assay to Run with Simplexa COVID-19 Direct Assay

By LabMedica International staff writers
Posted on 08 Jul 2020
Print article
Image: LIAISON® MDX (Photo courtesy of DiaSorin Molecular LLC)
Image: LIAISON® MDX (Photo courtesy of DiaSorin Molecular LLC)
DiaSorin Molecular LLC (Cypress, CA, USA) has CE marked its Simplexa Flu A/B & RSV Direct Gen II kit to run alongside its Simplexa COVID-19 Direct kit.

DiaSorin’s latest generation Simplexa Flu A/B & RSV Direct Gen II kit delivers continued comprehensive strain coverage and accurate detection in an efficient and trusted sample-to-answer format that does not require extraction. Collectively, over 100 Flu A, Flu B and RSV strains have been validated, including the 2020/2021 influenza vaccine strains. The Simplexa Flu A/B & RSV Direct Gen II assay is designed for use with the LIAISON MDX instrument.

The upcoming 2020/2021 flu season in the US will be complicated by the presence of SARS-CoV-2 also circulating in the community. Viral infections caused by Flu A, Flu B, RSV and SARS-CoV-2 have similar clinical presentations, although the treatment options are different, thus making it important to differentiate. Additionally, co-infection with SARS-CoV-2 and influenza A or B has been shown to cause increased severity of respiratory disease and the need for a combination therapy. The accurate diagnosis of the virus causing the infection can have major implications for the management of therapeutic regimens, infection control and community mitigation efforts.

The Simplexa Flu A/B & RSV Direct Gen II assay provides flexibility in workflow management for the upcoming flu season as the assay can be run alone or alongside the Simplexa COVID-19 Direct kit. The assays are designed to be performed at the same time allowing for differential diagnosis of COVID-19, influenza, and RSV. DiaSorin has also submitted the new assay to the FDA for 510(k) clearance.

“We met our goal to have the Simplexa Flu A/B & RSV Direct Gen II assay available in time for use during the upcoming Flu season and for patient samples to be tested, when needed, alongside the COVID-19 Direct assay,” said Michelle Tabb, chief scientific officer of DiaSorin Molecular. “This flu season the ability to detect and differentiate between influenza, RSV and COVID-19 will be vital and we are pleased to contribute to this solution.”

Print article


Molecular Diagnostics

view channel
Image: Micrograph of gold nanostar biosensors used to detect cancer-related microRNAs (Photo courtesy of Duke University School of Engineering)

Nanostar Biosensors Use Raman Scattering for Direct Detection of Cancer-Related MicroRNAs

A novel non-invasive nanoparticle-based assay detects cancer-related microRNAs without use of labels or target amplification. MicroRNAs (miRNAs) comprise a class of about 20 nucleotides-long RNA fragments... Read more

Industry News

view channel
Image: ChemWell RPR Analyzer (Photo courtesy of Awareness Technology, Inc.)

Awareness Technology Announces ChemWell RPR Analyzer - The Most Significant Innovation in Syphilis Testing in Last 30 Years

Awareness Technology, Inc. (Palm City, FL, USA) has announced the most significant innovation in syphilis testing in the last 30 years with the launch of the ChemWell RPR automated nontreponemal analyzer... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.